Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy
Phase 2
Completed
- Conditions
- HypogonadismChronic Obstructive Pulmonary Disease
- First Posted Date
- 2010-02-03
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- QuatRx Pharmaceuticals Company
- Target Recruit Count
- 15
- Registration Number
- NCT01061970
Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors
Phase 2
Completed
- Conditions
- HypogonadismErectile Dysfunction
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- QuatRx Pharmaceuticals Company
- Target Recruit Count
- 72
- Registration Number
- NCT00415571
- Locations
- ๐บ๐ธ
Office of Stephen Miller, Las Vegas, Nevada, United States
๐บ๐ธGenova Clinical Research, Tucson, Arizona, United States
๐บ๐ธHealthStar Research, Hot Springs, Arkansas, United States
Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2006-09-08
- Last Posted Date
- 2006-09-08
- Lead Sponsor
- QuatRx Pharmaceuticals Company
- Target Recruit Count
- 150
- Registration Number
- NCT00373516
- Locations
- ๐บ๐ธ
Clinical Research Site, San Antonio, Texas, United States
A Preliminary Clinical Study to Evaluate Fispemifene in the Treatment of Hypogonadism
Phase 2
Completed
- Conditions
- Hypogonadism
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2008-03-03
- Lead Sponsor
- QuatRx Pharmaceuticals Company
- Target Recruit Count
- 100
- Registration Number
- NCT00290134
- Locations
- ๐บ๐ธ
Clinical Research Site, Seattle, Washington, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath